Abstract:IMPORTANCE Loss of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure. OBJECTIVE To investigate the postoperative prognostic significance of MGMT in patients with resectable gastric cancer and its responsiveness to fluorouracil-based adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS This study recruited 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy between August 1, 2007, and December 30, 2008, at Zhongshan Hospital at Fudan University in Shanghai, China. Patients were randomly divided into a discovery data set (n = 200) and a validation data set (n = 245), and the range of follow-up time was from 2 to 76 months for the discovery group and 2 to 79 months for the validation group. The immunoreactivity for MGMT in cancer cells was reviewed under a light microscope by 2 pathologists who were blinded to the clinicopathological data. The association of MGMT expression with clinicopathological characteristics and measures and prognosis was inspected. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016. MAIN OUTCOMES AND MEASURES Estimates of overall survival on the basis of MGMT expression and hazard ratio (HR) for estimates of overall mortality risk. RESULTS Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. Positive expression of MGMT indicated better overall survival for patients with stage II or III gastric cancer in both the discovery data set (HR, 0.52; 95% CI, 0.32-0.84; P =.003) and the validation data set (HR, 0.63; 95% CI, 0.43-0.93; P =.01). Multivariate analysis identified MGMT expression and TNM stage as 2 independent prognostic factors for overall survival. In stage II disease, the benefit from fluorouracil-based adjuvant chemotherapy was superior among MGMT-positive patients (HR, 0.35; 95% CI, 0.13-0.95; P =.007 for interaction) compared with MGMT-negative patients. CONCLUSIONS AND RELEVANCE Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor. Incorporating MGMT expression into the current TNM staging system could lead to better prognostic accuracy. These findings should be confirmed within the framework of randomized clinical trials associated with genomic DNA sequencing studies.

Expressions and the Clinical Significance of MGMT, Hmlh1 in Human Gastric Carcinoma

The relationships between the expression of MGMT and prognosis in the advanced patients with gastric carcinoma

Expression of Mismatch Repair Genes Hmlh1 and Hmsh2 in Gastric Carcinoma and Their Clinicopathological Significance

The Clinical Significance of MGMT, Hmlh1 and Hmsh2 Gene Expressions in Gallbladder Adenocarcinoma and Adjacent Tissues

Expression and Significance of Mismatch Repair Gene and Osteoprotegerin in Human Gastric Carcinoma

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.

Expression of hMLH1 gene in gastric cancer and its significance

Expression and clinical significance of O6-methylguanine DNA methyltransferase in cervical cancer tissues

Expressions of p53 and hMSH2 in colon carcinoma

Expression of Dnmt1, Demethylase, MeCP2 and Methylation of Tumor-Related Genes in Human Gastric Cancer.

Expression of MGMT in Hepatocellular Carcinoma and Their Clinical Significance

Aberrant DNA Methylation of MGMT and Hmlh1 Genes in Prediction of Gastric Cancer.

The Expression of Human Macrophage Metalloelastase Mrna in Gastric Cancer Cell Lines and Tissues and Its Clinical Significance

Expressions of Hmlh1, Hmsh2, C-Myc, and PTEN in Gastric Remnant Cancer and Their Significance

[The Expression of O6-methylguanine DNA Methyltransferase and P53 in Non-Small Cell Lung Cancer and the Association with the Prognosis].

Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and Its Use As a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis

Expressions of MCM7 and p27 in gastric carcinoma tissues and their clinical significance

Aberrant DNA Methylation of P16, MGMT, and Hmlh1 Genes in Combination with MTHFR C677T Genetic Polymorphism in Gastric Cancer.

Expression of MGMT,hMLH1 and hMSH2 and its clinopathological signifi-cance in pancreatic carcinoma tissues

Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer

Clinicopathological Features And Prognostic Value Of Mismatch Repair Protein Deficiency In Gastric Cancer